Although wet and dry age-related macular degeneration affect the same part of the eye, they develop in different ways and therefore require different approaches to care. Understanding that distinction is important when considering macular degeneration treatment, because an option that is effective for wet AMD may have no role in dry AMD, and vice versa. Treatment also depends on the stage of the condition, how quickly it is progressing, and the individual patient’s overall eye health.
Age-related macular degeneration, usually shortened to AMD, affects the macula, the central part of the retina responsible for detailed straight-ahead vision. Damage to this area can make activities such as reading, recognizing faces, and driving increasingly difficult, although AMD does not normally cause total blindness. Dry AMD is by far the more common form and usually progresses gradually, while wet AMD is less common but can cause much faster changes in vision.
How Dry AMD Develops
Dry AMD occurs as the macula gradually becomes thinner and changes with age. It is generally divided into early, intermediate, and late stages, and people may have few or no noticeable symptoms during the earlier stages. Progression can take place over many years, although the rate varies considerably between individuals.
Because there is no single treatment that reverses early dry AMD, management often focuses on monitoring the condition and reducing factors that may contribute to progression. Regular eye examinations are important because they allow an eye specialist to look for changes before the patient necessarily notices a major difference in vision.
Lifestyle can also form part of the overall approach. Smoking cessation, regular physical activity, and a balanced diet are commonly encouraged as part of maintaining eye and general health. People with AMD should discuss their individual risk factors with an eye-care professional rather than relying on lifestyle changes as a substitute for medical monitoring.
Supplements Have a Specific Role
Certain vitamin and mineral supplements may be recommended for some people with AMD, but they are not suitable for everyone with the condition.
The AREDS2 formulation was developed following large clinical studies and may reduce the risk of progression to advanced AMD in people at certain stages of the disease. It is generally considered for people with intermediate AMD or certain cases where advanced AMD has developed in one eye.
This is different from taking an ordinary multivitamin for general eye health. The formulation contains specific amounts of nutrients, including antioxidants and minerals, and should be discussed with an eye-care professional before use. People with early AMD do not automatically benefit from taking AREDS2 supplements simply because they have received an AMD diagnosis.
Treating Advanced Dry AMD
Late dry AMD can lead to geographic atrophy, where areas of retinal cells gradually deteriorate. Historically, treatment options for this stage were extremely limited, with care largely focused on monitoring and helping patients make the best use of their remaining vision.
That situation has begun to change in the United States. New injectable medicines that target part of the immune system known as the complement pathway have been approved for geographic atrophy. These treatments are designed to slow the enlargement of areas of atrophy rather than restore vision that has already been lost.
This distinction is important. Slowing progression can still be valuable, but patients should have realistic expectations about what treatment is intended to achieve. Eligibility, potential benefits, injection frequency, and possible risks need to be considered with a retinal specialist.
For people whose vision has already been significantly affected, low-vision rehabilitation may also play an important role. Magnification, improved lighting, electronic aids, and practical adaptations can help people continue everyday activities even when the underlying retinal damage cannot be reversed.
Wet AMD Is Treated Differently
Wet AMD develops when abnormal blood vessels grow beneath or within the retina. These vessels are fragile and can leak fluid or blood, damaging the macula and causing relatively rapid changes in central vision.
Because wet AMD can progress quickly, prompt assessment is especially important. A sudden increase in distortion, new blurring, or straight lines appearing wavy should be evaluated by an eye-care professional without delay.
The main treatment for wet AMD is anti-VEGF medication.
VEGF stands for vascular endothelial growth factor, a protein involved in the formation of new blood vessels. In wet AMD, excessive VEGF activity contributes to the abnormal vessel growth responsible for leakage and retinal damage.
Anti-VEGF medicines are injected directly into the eye and work by blocking this process. They can reduce leakage, control abnormal blood vessel growth, and help preserve vision. In some patients, vision may improve following treatment.
Why Wet AMD Often Requires Repeated Injections
One injection is generally not enough to control wet AMD permanently. Anti-VEGF medicines work for a limited period, so patients typically require repeated treatment.
Injections may initially be given relatively frequently, with the schedule adjusted according to how the eye responds. Some patients eventually need treatment less often, while others require ongoing injections over a long period.
The exact schedule depends on the drug being used, retinal scans, visual changes, and the specialist’s assessment. Treatment plans are therefore individualized rather than following one identical timetable for every patient.
Although the idea of an injection into the eye can understandably sound uncomfortable, numbing medication is used beforehand and the procedure itself is usually brief. The eye is also carefully cleaned to reduce the risk of infection.
Photodynamic Therapy Has a Smaller Role
Wet AMD can also sometimes be treated using photodynamic therapy, although it is much less commonly used than anti-VEGF injections.
Photodynamic therapy involves giving a light-sensitive drug, usually through a vein, and then activating it with a specially targeted laser in the eye. The treatment damages abnormal blood vessels while limiting injury to surrounding tissue.
Today it may be used in selected circumstances or alongside anti-VEGF treatment rather than as the standard treatment for most people with wet AMD.
Dry AMD Can Become Wet AMD
Another important difference between the two forms is that they are not completely separate conditions.
A person with dry AMD can later develop wet AMD. This means someone who has been told their condition is dry should still pay attention to new or sudden changes in vision.
Monitoring can include regular professional eye examinations and, where advised, checking vision at home. A noticeable change should not simply be assumed to be part of the gradual progression of dry AMD.
Early recognition matters because wet AMD treatment is generally aimed at preventing further retinal damage before more vision is permanently lost.
Monitoring Is Important for Both Forms
Although treatments differ considerably, ongoing monitoring is important in both wet and dry AMD.
People with wet AMD may have retinal imaging regularly to assess whether fluid or abnormal blood vessel activity is still present and to help determine when another injection is needed. People with dry AMD may be monitored for progression or for signs that the condition has changed into the wet form.
Regular appointments also provide an opportunity to discuss practical changes in vision. Someone may notice difficulty reading small print, adjusting to dim lighting, driving, or recognizing faces before they describe their vision simply as being “worse.”
These details can help an eye-care professional understand how the condition is affecting everyday life.
Different Conditions, Different Goals
The major difference between wet and dry AMD treatment comes from the biology of the two forms. Wet AMD is driven by abnormal blood vessel growth and leakage, which can be targeted with anti-VEGF drugs. Dry AMD involves gradual degeneration of retinal tissue, so treatment and monitoring have traditionally focused more heavily on slowing progression and supporting remaining vision.
New therapies for geographic atrophy mean the treatment landscape for advanced dry AMD is changing, but the goals are still not identical to those of wet AMD treatment. In either case, earlier assessment gives patients and specialists more opportunity to determine which options are appropriate.
Macular degeneration cannot always be reversed, but there is a significant difference between assuming nothing can be done and receiving care tailored to the particular type and stage of AMD. Anyone experiencing new distortion, sudden central blurring, or another significant change in vision should seek prompt professional assessment rather than waiting for a routine eye appointment.
